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Abstract 
Trabecular bone score (TBS) index has recently been obtained as a result of textural greyscale analysis of DXA images. Because it enables the 
assessment of bone microarchitectural texture, TBS may be useful in evaluating bone quality. This study explores the current knowledge 
of the use of TBS in patients with endocrine disorders with co-occurring bone structure changes. Currently, the clinical importance TBS 
was verified in terms of disorders of the growth hormone/insulin-like growth factor 1 (GH/IGF-I) axis, glucocorticoid excess, thyroid and 
parathyroid disease, as well as in diabetes mellitus type 1 and 2.
It has been clarified that patients suffering from various endocrinopathies are a group in which TBS should be used routinely because it 
correlates with clinical factors and may improve patient management in various endocrine disorders. (Endokrynol Pol 2019; 70 (4): 350–356)
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Introduction 
Osteoporosis, fragility fractures, and risk 
assessment tools
Osteoporosis is considered to be the most common of 
all bone diseases [1], affecting over 200 million people 
worldwide. It is characterised by bone microarchitec-
tural abnormalities resulting in altered bone quality 
and decreased bone strength. Altogether, these changes 
result in an increased risk of fractures, totalling as much 
as 9 million occurrences per year [2–4]. Unfortunately, 
these cause significant morbidity and mortality; hip 
fractures alone are believed to be linked with more 
than 700,000 deaths [5]. Therefore, it is very important 
to identify individuals capable of fragility fractures in 
the near future, in order to initiate proper treatment 
and minimise the risk.
Dual-energy X-ray absorptiometry (DXA) is a key 
tool used in fracture risk assessment. With its use, bone 
mineral density (BMD) can be measured. BMD is the 
reference standard for diagnosis of osteoporosis, as 
well as the fracture risk stratification [5]. It has been 
proven that each standard deviation (SD) decrease in 
BMD results in a 1.4-fold to 2.6-fold increase in the risk 
of fracture [6]. On the other hand, most individuals 
with fragility fractures show normal BMD values or 
osteopaenia, which complicates the comprehensive di-
agnosis. The main reason for that is that DXA gives only 
information regarding bone density, without assesing 
the bone microarchitecture. Impaired architecture, 
which is independent of BMD, is associated with greater 
risk of fracture [7]. Therefore, it is essential to identify 
other skeletal and extra skeletal risk factors that would 
contribute to better selection of patients who request 
immediate treatment [8–10].
There are several easily assessable clinical risk factors, 
including age, smoking, alcohol intake, glucocorticoid 
use, as well as previous fragility fracture or parental his-
tory of hip fracture, which have an impact on fracture 
risk independent of measured BMD. This has resulted 
in the development of additional assessment tools, e.g. 
FRAX. FRAX can be used to establish the 10-year prob-
ability of hip and major osteoporotic fracture (MOF), 
validated in independent cohort studies [11–14].
Additionally, there are also skeletal parameters, such 
as bone geometry, microarchitecture, microdamage, rate 
of mineralisation, and rate of bone turnover, which, 
as well as BMD, contribute to bone strength and risk 
of fracture [1, 8, 15, 16]. For example, high-resolution 
peripheral quantitative computed tomography was 
designed to assess the bone microstructure, leading to 
the ability to differentiate between women with and 
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>1.350 units is considered to be normal; TBS between 
1.200 and 1.350 is connected with partially degraded 
microarchitecture; and TBS < 1.200 should define de-
graded microarchitecture [23]. The existing literature 
indicates that low lumbar spine TBS is associated with 
a history of fracture and the incidence of new fracture. 
The effect is largely independent of BMD and is of 
sufficient magnitude to enhance risk stratification 
with BMD [2].
TBS and bone microarchitecture
It has been shown that TBS strongly correlates positive-
ly with trabecular bone volume (BV) to tissue volume 
(TV) ratio (BV/TV). It also correlates with the number 
of trabeculae, their stiffness, and their connectivity. 
TBS correlates negatively with intra-trabecular space 
and structure model index [24]. Another ex vivo study 
confirmed strong negative associations between TBS 
and structure model index, as well as positive cor-
relations with number of trabeculae and BV/TV ratio. 
These correlations were adjusted according to one’s age, 
sex, past vertebral fracture, and LS-BMD [20]. What is 
more, concerning ex vivo studies, significant correlations 
between TBS and bone volume fraction were found in 
trabecular spacing and trabecular number in cadaveric 
vertebral, femoral neck, and distal radius samples.[25] 
Other researchers found that TBS correlates with vari-
ous microarchitectural bone parameters in patients with 
idiopathic osteoporosis [20]. To sum up, ex vivo studies 
stated that TBS provides an indirect measure of bone 
microstructure characteristics [2, 14, 17, 19, 20, 26, 27].
Several in vivo studies that compared TBS with 
central quantitative computed tomography found 
correlations between TBS and lumbar spine trabecular 
volumetric BMD, as well as trabecular and cortical 
parameters of the femoral neck and hip. This was, 
however, significant only without adjustments for ages, 
BMI, BMD, and ethnicity [5, 28]. This means that TBS 
may not fully capture all aspects of bone microstructure, 
which can be now assessed by high-resolution imaging 
procedures [12].
TBS limitations
Like other clinical management tools, TBS is charac-
terised by several limitations, including clinical and 
technical aspects. It has been shown, for example, that 
as the DXA image resolution degrades, so the TBS value 
increases [24]. It has also been indicated that the thick-
ness of soft tissue underlying the spine can result in 
decreased TBS values [29]. What is more, a dependence 
of TBS on BMI, body composition, and age has been 
found [30, 31]. The excessive amount of abdominal 
soft tissue can also be a reason for overestimated TBS 
values [32].
without fragility fractures [12]. This is, however, used 
only as a research tool.
Recently, the trabecular bone score (TBS) index 
has been introduced as a result of textural greyscale 
analysis of DXA images. As it enables the assessment 
of bone microarchitectural texture, TBS may be useful 
in evaluating bone quality. Going further, it may be 
an independent and additional instrument for assess-
ment of bone, as well as other clinical risk factors and 
FRAX [17, 18].
Trabecular bone score
Definition
Trabecular bone score is a textural index that is a result 
of computed evaluation of pixel grey-level variations 
in lumbar spine DXA images. Therefore, it provides 
an indirect index of bone microarchitecture. As a result 
of a computed score of the two-dimensional plane 
of three-dimensional bone structure, obtained from 
DXA imaging, TBS can be used as an index of the bone 
microstructure state. It is strongly connected with 3D 
bone characteristics such as the trabecular number, the 
trabecular separation, and the connectivity density [2, 
4, 17, 19, 20].
Because TBS uses previously obtained DXA im-
ages, it enabled the generation of longitudinal data 
concerning cross-sectional and clinical studies. This 
also allows direct comparison with areal BMD (aBMD) 
and application to existing datasets. As such, there is 
now strong evidence that TBS can differentiate between 
two three-dimensional (3D) microarchitectures that 
exhibit the same bone density but different trabecular 
characteristics.
TBS evaluation results
In clinical practice, the TBS is calculated in a second by 
currently commercially available software. The software 
can be applied prospectively or retrospectively to any 
standard DXA images obtained with the use of modern 
fan beam densitometers.
An elevated TBS appears when there is a strong, 
fracture-resistant bone microarchitecture found. A low 
TBS indicates weak bone, prone to fractures. It has been 
shown that low TBS is associated with fewer, widely 
distributed, and poorly connected trabeculae, while 
high TBS values correlate with stronger trabecular 
structure.
Trabecular bone score cut-off points classifying 
normal and abnormal TBS values have not yet been 
defined. The only available TBS range is one that has 
been proposed for postmenopausal women [21–23].
The following normal range for TBS values in 
postmenopausal women has been proposed: TBS 
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Trabecular bone score in endocrine disorders
Disorders of the growth hormone/insulin-like 
growth factor 1 (GH/IGF-I) axis
Acromegaly is a rare chronic disease caused by excess 
secretion of GH, most often from an adenoma of the 
pituitary gland [33]. The condition is considered to be 
associated with an increased risk of fragility fractures, 
even when the bone mineral density (BMD) is within 
normal range. This indicates that GH/IGF-I overpro-
duction may influence the bone microarchitecture [34]. 
Hong et al. suggested TBS as a useful tool in the assess-
ment of skeletal fragility in acromegaly. The results of 
the study showed that lumbar spine TBS was lower 
in acromegaly patients than in controls for both men 
and women (1.345 ± 0.121 vs. 1.427 ± 0.087, p = 0.005 
in men; 1.356 ± 0.082 vs. 1.431 ± 0.071, p = 0.001 
in women). However, BMD values at all sites were 
similar. Hypogonadal acromegaly patients had lower 
TBS values compared with male and female controls 
(1.333 ± 0.103 vs. 1.419 ± 0.098, p = 0.031; 1.339 ± 0.086 
vs. 1.415 ± 0.060, p = 0.001; respectively). To exclude 
the hypogonadal effect, the authors also compared eu-
gonadal patients with the control group. Lumbar spine 
TBS was significantly lower only in eugonadal women 
[33]. In another study, researchers investigated how 
the treatment of acromegaly affects TBS results, and 
observed a significant decrease in TBS value one year 
postoperatively in a subgroup of 38 subjects, whereas 
BMD values increased by 3.2 (±4.9)% (p < 0.01). No 
correlation was shown between the change in TBS 
and the following variables: GH, IGF-I, BMI, bone 
markers, 25(OH)D, BMD LS or change in BMD LS, and 
bone markers or IGF-I. These results may support the 
hypothesis that persisting increased risk of fracture is 
caused by changes occurring in trabecular bone archi-
tecture. On the other hand, the observed decrease of 
TBS may be attributed to the underestimation of TBS 
values due to fat accumulation mainly in central depots 
as a result of the treatment of acromegaly [35]. Valassi 
et al. investigated the relationship between TBS, spine 
volumetric BMD (LS vBMD) measured by quantitative 
computed tomography (QCT), and fat depots in acro-
megaly and healthy controls. Both LS vBMD and TBS 
were inversely correlated with epicardial adipose tissue 
(EAT) in the acromegaly group (q = –0.69, p = 0.001; 
q = –0.56, p = 0.015, respectively). 
Although growth hormone deficiency (GHD) is also 
associated with alteration of bone architecture, research 
concerning the usage of TBS in these patients is still 
limited. The first prospective study assessed the effect 
of two-year growth hormone replacement therapy on 
TBS in a subgroup of 32 subjects with GHD. The high-
est increase in TBS value was observed at the level of 
vertebra L4 (4%, p = 0.02) after two-year recombinant 
human GH (rhGH) treatment. Lumbar spine and femur 
BMD were recorded in the whole group of 147 GHD 
patients (age 35.1 years, 84 males/63 females, 43 cases 
of childhood onset GHD/104 cases of adult onset GHD) 
and increased significantly during a two-year period 
of treatment (14% and 7% increase, respectively) [36]. 
The second study on a group of 18 adult GHD patients 
(mean age, 37.39 ± 12.42 years) demonstrated that 
over a seven-year treatment time TBS remained at the 
baseline level (no statistically significant differences) 
whereas lumbar spine BMD increased (p = 0.01) [37].
Glucocorticoids and TBS
It is well established that both exogenous and endog-
enous glucocorticoid excess is associated with increased 
fracture risk often independently of BMD [38–40]. 
Eller-Vainicher et al. demonstrated on a cohort of 102 
subjects with adrenal incidentaloma (AI) that patients 
with subclinical hypercortisolaemia (SH) had lower 
LS-BMD, FT-BMD, and TBS than patients without SH 
and controls. Additionally, TBS values were lower in 
subjects without SH compared with the control group. 
Logistic regression analysis revealed that low TBS alone 
and the combination of low TBS and low LS-BMD were 
both associated with the presence of vertebral frac-
tures. No such association was found for low LS-BMD 
alone. Accordingly, the combination of normal TBS and 
normal LS-BMD was associated with the absence of ver-
tebral fractures. Finally, TBS predicted the occurrence 
of a new fracture in a subgroup of 40 subjects followed 
for 24 months independently of LS-BMD, BMI, and 
age [38]. A study on 51 Caucasian women with AI also 
showed TBS impairment in comparison with normal 
TBS values for age, while no differences were found for 
BMD. Hypogonadism and hypercortisolism presented 
a negative effect on TBS but not on BMD [41]. Another 
study concerning the risk factors for fracture in en-
dogenous Cushing’s syndrome (CS) patients revealed 
that the only predictor of low traumatic fracture, after 
adjustment for age, gender, BMD, and TBS was the level 
of free cortisol in 24-hour urine sample. However, the 
study sample had low TBS, and the bone microarchi-
tecture was classified as mainly degraded (49.5%) or 
partially degraded (34%) according to the previously 
described definitions for postmenopausal women [42]. 
A recent cross-sectional study on a group of 608 women 
(mean age 65.5 years) by Kuehner et al. investigated the 
relationship between salivary cortisol circadian rhythm 
and TBS. The subjects in the highest tertile of 8PM 
salivary cortisol (sc-8PM) had lower TBS values than 
the subjects in the lowest tertile (1.27 vs. 1.29; p = 0.02). 
Radiologic VFx prevalence was associated with sc-8PM 
and TBS independently of each other and of other risk 
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factors including age and lumbar spine BMD. These 
results support the findings from previous studies on 
patients with adrenal incidentaloma [39]. 
There are few studies attempting to examine the 
influence of treatment with glucocorticoids on TBS. 
Paggiosi et al. studied the ability of LS-BMD, TBS, 
and LS-BMD combined with TBS (LS-BMD+TBS) to 
discriminate between glucocorticoid-treated women 
(prednisolone ≥ 5 mg/day or equivalent for > 3 months), 
women with recent fractures (≤ 6 months since fracture 
of the distal forearm, proximal humerus, vertebra or 
proximal femur), and glucocorticoid-naive, healthy 
women without fractures. The essential conclusions 
of the research are that TBS was able to discriminate 
between women with recent fractures and healthy 
women without fractures, and also between glucocor-
ticoid-treated women and healthy, glucocorticoid-naive 
women, independently of LS-BMD [40]. Similarly, in 
a study on 1520 men and women aged 40 years or 
more, TBS was reported to be decreased in GC-treated 
patients compared with matched controls (1.267 
vs. 1.298, p < 0.001), whereas there was no difference 
in BMD at any site. The same results were obtained 
when the sample was divided according to sex. GC 
patients with fracture showed significantly lower TBS 
values than subjects without fracture. An association 
between TBS and the presence of fracture was also 
observed [43]. The studies on patients with systemic 
sclerosis and rheumatoid arthritis demonstrated that 
TBS was significantly lower in subjects treated with 
GC compared with non-treated subjects and was also 
lower in patients with fractures compared with those 
without fractures [44, 45].
Primary hyperparathyroidism
Primary hyperparathyroidism (PHPT) is known to be 
associated with cortical bone loss and increased fracture 
risk. A prospective study on a group 92 PHPT patients 
(74 females, age 62.1 ± 9.7 years) and 98 control subjects 
assessed the association of vertebral fracture and TBS. 
PHPT patients had lower TBS and higher VFx preva-
lence (43.5%) than the control group. The logistic regres-
sion analysis showed that TBS was associated with VFx 
(odds ratio 1.4, 95% CI: 1.1–1.9, p = 0.02) regardless of 
LS-BMD, age, BMI, and gender. In a subgroup of 20 
surgically treated patients at a two-year follow-up, 
TBS increased significantly, while in patients who were 
treated conservatively TBS decreased significantly in 
those with incident VFx as compared to those without 
[46]. In accordance with these findings, Romagnoli et 
al. showed that mean TBS values were significantly 
lower in PHPT than in controls (1.19 ± 0.10, 1.24 ± 0.09; 
respectively, p = 0.01) and that TBS was also decreased 
in PHPT subjects with vertebral fractures in comparison 
with those without fracture (1.14 ± 0.10, 1.24 ± 0.09, 
respectively, p = 0.001). It was also concluded that the 
presence of vertebral fractures in PHPT patients was 
independently associated with the reduction of TBS 
(OR = 0.003, 95% CI: 0–0.534, p = 0.028) and the in-
crease of years since menopause (OR = 1.076, 95% CI: 
1.017–1.139, p = 0.011), but not with age, the increase 
of BMI, and the reduction of LS-BMD [47]. In other 
study, the authors evaluated differences in TBS in as-
ymptomatic hyperparathyroidism [24 normocalcaemic 
hyperparathyroidism (NHPT) and 15 hypercalcaemic 
hyperparathyroidism (HHPT)]. TBS and BMD (all sites) 
were similar in both subgroups. Asymptomatic HPT 
subjects were characterised by significantly higher 
parathyroid hormone (PTH) and significantly lower 
TBS and areal BMD at all sites. A significant negative 
relationship between TBS and PTH was found in as-
ymptomatic HPT patients, after adjustment for age, 
sex, and BMI. These results may reflect a possible role 
of PTH in bone microarchitecture alteration [48]. Silva 
et al. evaluated TBS in relation to HRpQCT measure-
ments of volumetric bone density, skeletal microarchi-
tecture, and bone stiffness in a cross-sectional study 
on 22 postmenopausal women with PHPT. TBS values 
correlated with whole bone stiffness and all HRpQCT 
indices, except for trabecular thickness and trabecular 
stiffness at the radius. At the tibia, correlations were 
noted between TBS and volumetric densities, cortical 
thickness, trabecular bone volume, and whole bone 
stiffness. After adjustment for body weight, TBS was 
correlated with all indices of trabecular microarchitec-
ture except trabecular thickness [49].
Other authors focused on the relationship between 
vitamin D and TBS in PHPT patients. The first study 
revealed no differences in TBS values between the three 
following groups: vitamin D level < 20 ng/mL, 20–29 
ng/mL, and ≥ 30 ng/mL even after adjusting for age, sex, 
weight, and GFR [50]. The second study was designed 
as an investigator-initiated, double-blind, randomised, 
placebo-controlled, parallel-group trial and comprised 
a study group of 46 PHPT patients (35 women, 11 men; 
mean age 58 years). The patients were supplemented 
with 70 µg (2800 IU) of cholecalciferol or placebo for 26 
weeks before parathyroidectomy (PTX) and 26 weeks 
following PTX. TBS did not change in response to 
vitamin D treatment but improved significantly after 
PTX [51].
Thyroid diseases
In patients with higher fT4 levels within the normal 
reference values deterioration of trabecular microar-
chitecture was observed. This, however, particularly 
affected postmenopausal, healthy euthyroid women. 
The relationship between thyroid hormone levels and 
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bone parameters revealed negative association be-
tween TBS of L1-4 and fT4 levels (b = –0.11, p = 0.002) 
[52]. The comparative study concerning pre- and 
postmenopausal patients with differentiated thyroid 
carcinoma (DTC) receiving long-term TSH suppressive 
therapy (TST) revealed that postmenopausal women 
with DTC receiving TST had lover TBS, compared to 
premenopausal patients. These TBS changes did not 
co-occur with BMD loss [53]. Similar results concern-
ing TST in group of postmenopausal DTC patients 
were confirmed by other authors, also indicating that 
more than five years of TST resulted in lower lumbar 
spine TBS values compared to patients with therapy 
of less than three years (1.335 ± 0.092 vs. 1.296 ± 0.078, 
p = 0.015) [54].
Other studies based on a group of premenopausal 
women showed that Graves’ Disease is in strong cor-
relation with decreased TBS, whereas the BMD still did 
not differ between active the Graves’ Disease group and 
the control group [55].  
Diabetes mellitus
Patients with diabetes mellitus (type 1 and type 2) are 
predisposed to higher fracture risk [56]. When com-
pared to controls, bone mineral density is decreased 
in type 1 diabetes mellitus (T1DM) and increased in 
type 2 diabetes mellitus (T2DM), which suggests that 
alterations in bone quality play an important role in 
the development of fragility fractures in this group of 
patients [56–58]. In a recent study, a cohort of T1DM 
patients with prevalent fractures showed a signifi-
cantly lower TBS than T1DM patients without fractures 
(1.309 ± 0.125 vs. 1.370 ± 0.127, p = 0.04). Lower TBS 
and HbA1c were independently associated with the 
occurrence of fractures in T1DM subjects [57].
There are several available studies demonstrating 
that in patients with T2DM, TBS values are decreased 
and BMD values are increased when compared to 
non-diabetic subjects [58–61]. What is more, among 
T2DM patients, TBS seems to have higher values in 
subjects with good glycaemic control than in subjects 
with poor glycaemic control [58]. This is corroborated by 
another study, in which TBS was found to be negatively 
correlated with HbA1c, fasting plasma glucose, fasting 
insulin, and homeostasis model assessment — insulin 
resistance (HOMA-IR) [59]. These results show promise 
that TBS might be used to identify skeletal deteriora-
tion in T2DM patients in whom BMD only seems to 
be unsatisfactory [59]. A retrospective study on 169 
Korean postmenopausal women with T2DM showed 
that significantly lower TBS (p = 0.008) and higher 
TBS-adjusted FRAX scores were reported (p = 0.019) in 
the group with vertebral fractures (VFs) compared to the 
group without VFs. On the contrary, no significant dif-
ferences were seen between the two groups in terms of 
BMD and original FRAX scores [60]. Finally, a large-scale 
study on 29,407 women (50 years old and above, 2356 
of whom were diagnosed with diabetes) determined 
TBS as a BMD-independent predictor of fracture. TBS 
predicted fractures in patients with diabetes (adjusted 
hazard ratio 1.27, 95% CI: 1.10–1.46) and without diabe-
tes (hazard ratio 1.31, 95% CI: 1.24–1.38) [60].
Conclusions
Although TBS is a relatively young method, numerous 
studies confirm the importance of this technique in 
diagnostic and therapeutic procedures in patients with 
increased fracture risk. In this aspect, patients suffering 
from various endocrinopathies have become a group 
in which TBS should be used routinely, in combina-
tion with both aBMD and FRAX. The given clinical 
and scientific proof supporting the use of TBS, with its 
ability to be integrated in daily clinical practice, makes 
TBS an attractive, useful, and efficient clinical tool for 
physicians to improve patients’ management in various 
endocrine disorders.
Because TBS holds promise as an emerging tech-
nology that could well become a useful clinical tool in 
the diagnosis of fracture risk assessment, every effort 
should be made to ensure that the results of these pa-
tients are developed and published. Further research 
and clarification of the role of TBS in additional specific 
disorders is ongoing.
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